Pharmaceutical Technology Editors

Horizon Pharma reports that FDA has approved the use of Sanofi's manufacturing site in Compiegne, France to manufacture DUEXIS.

Myriad Genetics and AstraZeneca expand their companion diagnostic pact for AztraZeneca?s investigational drug candidate olaparib.

Regulatory Authorities Discuss Elemental Impurities Standards

Mylan completes expansion of its transdermal patch facility in Vermont.

Sanofi and POZEN sign a license agreement for the commercialization of omeprazole and aspirin combination product.

FDA inspections reveal possible inaccurate sterility testing.

Following passage in the California Assembly, the California State Senate passes legislation to specify requirements for dispensing biosimilars.

Otsuka's planned acquisition bolsters its pipeline in oncology and adds fragment-based drug-discovery technology.

Rockwell Collins will sell Kaiser Optical Systems to Endress+Hauser.

Meda will acquire Acton Pharmaceuticals.

BioReliance opens Clearance Services Laboratories in Maryland for downstream bioprocessing studies.

Endo will acquire Boca Pharmacal in multimillion dollar deal.

Agilent Technologies opens multimillion dollar Spectroscopy Technology Innovation Center in Australia.

CordenPharma will acquire Peptisyntha SA, based in Belgium.

Merck & Co gets FDA approval to manufacture bulk varicella at its in Durham, North Carolina for use in chickenpox and shingles vaccines.

Zealand will join efforts with Eli Lilly to design and develop therapeutic peptides for Type 2 diabetes and obesity.

CEO of Waters Corporation will retire within in the next two years.

Capsugel plans to acquire Bend Research to enhance its bioavailability-enhancement capabilities.

Baxter and Coherus Biosciences colaborate to develop and commercialize a biosimilar version of etanercept for Europe, Canada, and, Brazil.

A roundup of developments in global health and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

Novartis Ilaris, an interleukin-1 beta inhibitor, treats active system juvenile idiopathic arthritis.

Prequalification of Sanofi Pasteur?s Menomune vaccine makes it eligible for purchase by United Nations agencies.

Sobi's application for Orfadin oral suspension has been validated by EMA.

Hospira has initiated a voluntary nationwide user-level recall of Aminosyn II, due to a foreign particle included in the injection port.

BioReliance updates Big Blue Mouse Assay service to meet OECD test requirements.

The new director general has stepped into the European generic and biosimilar medicines industries at a challenging time when the trade association is facing numerous priority issues on the European agenda.

Akebia appoints new president and CEO.

A new standard from the International Society of Automation addresses information technology security solutions for manufacturing applications.

Pharmaceutical Product Development has acquired patient-recruitment contractor Acurian.

Cubist issued a voluntary recall of four lots of vials due to the presence of particulate matter.